Teva to drop depression treatment after trial fails
Aug 30 (Reuters) - Generic drugmaker Teva Pharmaceutical Industries Ltd said it will stop development of a depression treatment after a late-stage trial failed to show the drug was more effective than placebo.
The study was the third late-stage study that tested Nuvigil, or armodafinil, as an adjunct therapy in adults with major depression associated with bipolar I disorder.
While the first late-stage trial had positive results, the second trial failed.
Teva said it will not proceed with regulatory filings for the drug for treating bipolar-related depression. The drug is already approved to help adults who experience excessive sleepiness.
Teva said there will be no material impact to the company. The company's US-listed shares were up slightly at $38.43 in afternoon trading.
- Israel warns of long Gaza war as Palestinian fighters cross border |
- West agrees wider Russia sanctions as Kiev says forces near crash site |
- Court orders Russia to pay $50 billion for seizing Yukos assets |
- Man found dead trapped between elevator and shaft wall in NYC
- Wall Street yawns as deal news offsets data; Herbalife sinks